Evaluation of hematologic parameters in children with Down syndrome
Öz
Objective: Congenital hematological disorders are frequently observed in Down syndrome (DS). In this study, we aimed to investigate peripheral blood-derived inflammation biomarkers such as neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and eosinophil/monocyte ratio in patients with Down syndrome.
Material and Methods: Ninety-eight patients with karyotypically ascertained DS and 103 healthy controls were included. All subjects were divided into three age groups: 0-2 years (34 patients, 34 controls), 2-6 years (32 patients, 33 controls), and >6 years (32 patients, 36 controls). Demographic, clinical, and laboratory data between June 2010 and December 2021 were written from the file records from the pediatric allergy and immunology department.
Results: Lymphocyte, eosinophil, and EMR were found to be significantly lower in children with DS compared to controls in group 2 (2-6 years) and group 3 (>6 years). PLR was found to be higher in children with DS in group 2 and group 3. There was no statistically significant difference between DS and controls in group 1 (<2 years) in terms of all parameters.
In group 2 (2-6 years) and group 3 (>6 years), there was a statistically significant difference between DS and controls in terms of lymphocyte, eosinophil, PLR, and EMR variables (P>0.05).
Conclusion: We found significant differences among lymphocyte, eosinophil, PLR, and EMR in patients with DS. As a result, these parameters should be evaluated carefully for clinical outcomes.
Anahtar Kelimeler
Down syndrome, EMR, MLR, NLR, PLR
Kaynakça
- Referans1. Cocchi G, Mastrocola M, Capelli M, Bastelli A, Vitali F, Corvaglia L. Immunological patterns in young children with Down syndrome: is there a temporal trend? Acta Paediatr 2007; 96: 1479-1482.
- Referans2. Lockitch G, Singh VK, Puterman ML, Godolphin WJ, Sheps S, Tringle A, et al. Age-related changes in humoral and cell-mediated immunity in Down syndrome children living at home. Pediatr Res 1987; 22: 536–40.
- Referans3. Kuşkonmaz B, Çetin M. Down Sendromunda AML. Katkı Pediatri Dergisi 2004; 26:397.
- Referans4. Huggard D, Kelly L, Ryan E, McGrane F, Lagan N, Roche E, et al. Increased systemic inflammation in children with Down syndrome. Cytokine. 2020; 127: 154938.
- Referans5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88(1): 218-30.
- Referans6. Mertoglu C, Gunay M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2017; Suppl 1: S127-S131.
- Referans7. Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. Clin Appl Thromb Hemost. 2016; 22(5): 405-11.
- Referans8. Manuel V, Miana LO, Solla DJF, Fernandes N, Carrillo G, Jatene MC. Preoperative level of neutrophil‐lymphocyte ratio: Comparison between cyanotic and acyanotic congenital heart disease. J Card Surg. 2021; 36(4): 1376-1380.
- Referans9. Kim HS, Jung J, Dong SH, Kim SH, Jung SY, Yeo SG. Association between high neutrophil to lymphocyte ratio and delayed recovery from Bell’s palsy. Clin Exp Otorhinolaryngol. 2019; 12(3): 261-266.
- Referans10. Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil lymphocyte ratio and cardiovascular disease risk: A systematic review and meta-analysis. Biomed Res Int. 2018; 2703518.